Table 7 Selective clinical trials of CDK4/6 inhibitors or p53-targeted agents
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Drug | Target | Condition | Status | Phase | NCT identifier |
|---|---|---|---|---|---|
Palbociclib (PD0332991) | CDK4/6 | RB-positive metastatic PCa | Completed | 2 | NCT02059213 |
Palbociclib (PD0332991) | CDK4/6 | mCRPC | Not yet recruiting | 2 | NCT02905318 |
Ribociclib (LEE011) | CDK4/6 | mCRPC | Completed | 2 | NCT02494921 |
Ribociclib (LEE011) | CDK4/6 | RB-positive metastatic PCa | Recruiting | 2 | NCT02555189 |
Abemaciclib (LY2835219) | CDK4/6 | mCRPC | Recruiting | 2/3 | NCT03706365 |
Abemaciclib (LY2835219) | CDK4/6 | Locally advanced PCa | Recruiting | 2 | NCT04298983 |
Abemaciclib (LY2835219) | CDK4/6 | mCRPC | Not yet recruiting | 2 | NCT04408924 |
APR-246 | Mutant p53 | Refractory PCa | Completed | 1 | NCT00900614 |
Arsenic trioxide | Mutant p53 | Stage IV PCa | Completed | 2 | NCT00004149 |
